Drug Trial Radar · NCT05297578
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
Last checked: Nov 19, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
207
Actual
Start
Jun 15, 2022
Primary completion
Feb 15, 2023
Study completion Feb 15, 2023
Sponsor
- Lead sponsor
- Vaxcyte, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.
Conditions
- Pneumococcal Vaccines
Interventions
24-Valent Pneumococcal Conjugate VaccineBiological
0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
Pneumococcal 20-valent Conjugate VaccineBiological
0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After VaccinationTime frame: 7 days after vaccination
- Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After VaccinationTime frame: 7 days after vaccination
- Percentage of Subjects Reporting Unsolicited Adverse Events Within 1 Month After VaccinationTime frame: 1 month after vaccination
- Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs)Time frame: 6 months after vaccination
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Accel Research Sites-Birmingham Clinical Research Unit
Birmingham, Alabama
Accel Research Sites - DeLand Clinical Research Unit
DeLand, Florida
CenExel RCA
Hollywood, Florida
Precision Clinical Research
Sunrise, Florida
Meridian Clinical Research
Savannah, Georgia
Pivotal Research Solutions
Stonecrest, Georgia
Healthcare Research Network II, LLC
Flossmoor, Illinois
AMR Newton, formerly Heartland Research Associates
Newton, Kansas
AMR Wichita West
Wichita, Kansas
AMR New Orleans
New Orleans, Louisiana
Healthcare Research Network
Hazelwood, Missouri
Meridian Clinical Research
Omaha, Nebraska
Accellacare of Rocky Mount
Rocky Mount, North Carolina
Meridian Clinical Research
Cincinnati, Ohio
Accellacare of Charleston
Mt. Pleasant, South Carolina
Coastal Carolina Research
North Charleston, South Carolina
Clinical Trials of Texas, LLC
San Antonio, Texas
CenExel JBR Clinical Research
Salt Lake City, Utah
Velocity Clinical Research, Salt Lake City
West Jordan, Utah
Charlottesville Medical Research
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.